Skip to content

Advertisement

  • Research article
  • Open Access

Genetic polymorphisms and asthma: findings from a case–control study in the Madeira island population

  • †1, 5Email author,
  • 1,
  • 2,
  • 3,
  • 2,
  • 2,
  • 2,
  • †1, 4 and
  • †2
†Contributed equally
Biological Research201447:40

https://doi.org/10.1186/0717-6287-47-40

©  Berenguer et al.; licensee BioMed Central Ltd. 2014

  • Received: 19 March 2014
  • Accepted: 27 August 2014
  • Published:

Abstract

Background

Asthma is a complex disease influenced by multiple genetic and environmental factors. While Madeira has the highest prevalence of asthma in Portugal (14.6%), the effect of both genetic and environmental factors in this population has never been assessed. We categorized 98 asthma patients according to the Global Initiative for Asthma (GINA) guidelines, established their sensitization profile, and measured their forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) indexes. Selected single nucleotide polymorphisms (SNPs) were analysed as potential markers for asthma susceptibility and severity in the interleukin 4 (IL4), interleukin 13 (IL13), beta-2-adrenergic receptor (ADRB2), a disintegrin and metalloprotease 33 (ADAM33), gasdermin-like (GSDML) and the signal transducer and activator of transcription 6 (STAT6) genes comparatively to a population reference set.

Results

Although mites are the major source of allergic sensitization, no significant difference was found amongst asthma severity categories. IL4-590*CT/TT and IL4-RP2*253183/183183 were found to predict the risk (2-fold) and severity (3 to 4-fold) of asthma and were associated with a lower FEV1 index. ADRB2-c.16*AG is a risk factor (3.5-fold), while genotype GSDML-236*TT was protective (4-fold) for moderate-severe asthma. ADAM33-V4*C was associated to asthma and mild asthma by the transmission disequilibrium test (TDT). Finally, ADAM33-V4*CC and STAT6-21*TT were associated with higher sensitization (mean wheal size ≥10 mm) to house dust (1.4-fold) and storage mite (7.8-fold).

Conclusion

In Madeira, IL4-590C/T, IL4-RP2 253/183, GSDML-236C/T and ADAM33-V4C/G SNPs are important risk factors for asthma susceptibility and severity, with implications for asthma healthcare management.

Keywords

  • Asthma
  • Madeira
  • SNPs
  • Susceptibility
  • Severity

Background

Asthma is a chronic airway inflammation, characterized by variable airway obstruction and reduced lung function, and leading to wheezing and shortness of breath [1]. It is described as a complex disease arising from the contribution of multiple genetic and environmental factors [2, 3], affecting more than 300 million people worldwide, with increased prevalence in developed societies [4].

In Portugal, 7.83% of the population is affected by clinical asthma and 8.72% by wheezing symptoms [5]. Within Portugal, the island of Madeira has a high prevalence of the disease, as active asthma (presence of symptoms during the last 12 months) affects 14.6%, and atopy (positive reaction to skin prick tests (SPT) to common aeroallergens and the presence of specific IgE) affects 54% of the population [6].

Given the high prevalence of asthma in the Madeira population [6], determining the population’s genetic background is an essential first step towards understanding the mechanisms of the disease. In previous work [7] we showed that both IL4-590 and IL4-RP2 are useful genetic markers to detect asthma predisposition in the Madeira population. Investigating a larger number of genes is important because many genes with small effects, rather than just a few with strong effects, contribute to the disease risk [8]. A useful clustering of asthma susceptibility genes has been proposed [9]: i) triggers of the immune response (such as CD14, IL10, STAT3, MHC class II molecules); ii) regulators of the T helper 2 (Th2) differentiation (IL12B, IL4, IL13, STAT6, IL4RA); iii) associated with epithelial biology (CCL5, FLG, SPINK5, GSDML) and iv) linked to lung function, airway remodeling and asthma severity (ADRB2, ADAM33, DPP10, PHF11).

Here we extend our analysis in four important ways, to consider i) 6 additional polymorphisms, namely IL13-c.144 G/A, ADRB2-c.16 A/G, ADAM33-V4 C/G, ADAM33-S1 c.710 G/A, GSDML-236 C/T and STAT6-21 C/T (guided by a literature review summarized in Table 1), ii) the asthma persistence and severity classes according to GINA guidelines, iii) the most common allergens in the island and iv) the FEV1/FVC lung function indexes. Therefore, this work contributes to the analysis of the association of the above polymorphisms to asthma susceptibility and severity, FEV1/FVC indexes and sensitization profiles, in the Madeira population.
Table 1

Selected studies previously reporting association of the studied SNPs and asthma

Gene

Polymorphism

dbSNP rs ref (NCBI)

Chromosome location

Alleles (ancestral:derived)

References

IL13

c.144 Gln/Arg

rs20541

5q31 exon 4

G > A

[10–16]

IL4

590

rs2243250

5q31 promoter

C > T

[17–23]

IL4

RP2

-

5q31 intron 2

253 > 183(del)

[24]

ADRB2

c.16 Arg/Gly

rs1042713

5q31 exon

A > G

[25, 26]

ADAM33

V4

rs2787094

20p13 3’UTR

C > G

[27–30]

ADAM33

S1 c.710 Val/Ile

rs3918396

20p13 exon 19

G > A

[27]

GSDML

236

rs7216389

17q21 intron 1

C > T

[31–39]

STAT6

21

rs324011

12q13-24 intron 2

C > T

[19, 40–44]

Results

Demographic and clinical characterization of the asthmatics

The demographic and clinical characterization of the asthmatic population analysed in this study are shown in Table 2. The patients’ mean age was 13.6 ± 4.3 years old, with 59.2% males. None of the asthma persistence or severity phenotypes was found sub-structured by the male-to-female ratio. The FEV1 and FVC indexes were significantly different between mild persistent and moderate-severe persistent asthma (Mean FEV1 t = 2.732, p-value = 0.008; FVC Mann–Whitney U = 456.0, p-value = 0.025).
Table 2

Clinical characterization of the asthmatics study population

 

Study sample set

 

Overall asthma

Intermittent asthma

Persistent asthma

Mild

Moderate-severe

p-value

Sample size (n,%)

98 (100.0)

24 (24.5)

74 (75.5)

44 (59.9)

30 (40.5)

 

Male/Female (%)

59.2/40.8

62.5/37.5

58.1/41.9

54.5/45.5

63.3/36.7

 

Mean age (years + -s.d.)

13.6 + -4.3

14.1 + -3.5

13.4 + - 4.5

14.3 + -4.6

12.0 + - 4.1

 

Mean FEV1 (%)

96.9 + -14.7

98.5 + -16.3

96.4 + -14.2

99.9 + -10.7

91.2 + - 17.1

0.008

Mean FVC (%)

95.0 + -12.8

97.4 + -12.1

94.3 + -13.0

97.3 + -9.9

89.8 + -15.6

0.025

Asthma classification according to GINA [75].

A Shapiro-Wilk test showed that FEV1 is normally distributed (p > 0.05) while FVC is not (p = 0.008). Thus, a t-test was used for the analysis of FEV1 while a Mann–Whitney test was used for FVC. Statistically significant p-values were found for comparisons between mild persistent and moderate-severe persistent asthma, denoted in bold.

Although persistent asthmatics were found more frequently sensitized to both cat and dog allergen than intermittent asthmatics (Additional file 1) no significant differences were observed for SPT positivity or degree of sensitization to the most common allergens in the island, namely dust and storage mites mix fungi, indoor fungi, cat or dog.

SNP association to asthma risk and severity

The genotypic and allelic frequencies of each SNP among asthma subgroups and population reference set are described in Table 3 and Additional file 2, respectively. The genotypic distribution of SNPs in controls reflects previously published data on other European and Mediterranean populations [45, 46]. All SNP polymorphisms were found to be in HWE, except for STAT6-21 locus in mild persistent asthma (p-value = 0.038). Nevertheless, this SNP was considered in the analysis under a more stringent p-value cut-off of 0.01, since a slight deviation from HWE is allowed for SNPs linked to disease status [47].
Table 3

SNP genotypic frequencies for the Madeira reference set and asthmatics study population

SNP genotypes

Study sample set

 

Madeira reference set

Overall asthma

Intermittent asthma

Persistent asthma

Mild

Moderate-severe

 

105a

98

24

74

44

30

IL4-590 C/T

      

CC

0.800

0.643

0.708

0.622

0.705

0.500

CT

0.191

0.327

0.250

0.351

0.295

0.433

TT

0.009

0.031

0.042

0.027

0

0.067

p-value

 

0.009

 

0.006

 

0.002

OR (95%CI)

 

2.222 (1.191-4.146)

 

2.433 (1.264-4.717)

 

4.000 (1.701-9.434)

IL4-RP2 253/183

      

253253

0.818

0.694

0.792

0.662

0.750

0.533

183253

0.155

0.276

0.167

0.311

0.250

0.400

183183

0.027

0.031

0.042

0.027

0

0.067

p-value

 

0.027

 

0.013

 

0.002

OR (95%CI)

 

1.984 (1.040 -3.788)

 

2.296 (1.159 -4.547)

 

3.938 (1.657- 9.357)

IL13-c.144 G/A

      

GG

0.676

0.704

0.625

0.730

0.773

0.667

GA

0.305

0.267

0.333

0.257

0.205

0.333

AA

0.019

0.020

0.042

0.014

0.023

0

ADRB2-c.16 A/G

      

AA

0.181

0.194

0.250

0.176

0.250

0.067

AG

0.457

0.480

0.458

0.486

0.364

0.667

GG

0.362

0.327

0.292

0.338

0.386

0.267

p-value

     

0.010*

OR (95%CI)

     

3.500 (1.318-9.293)

ADAM33-V4 C/G

      

GG

0.029

0.010

0

0.014

0.023

0

CG

0.209

0.235

0.292

0.216

0.182

0.267

CC

0.762

0.755

0.708

0.770

0.795

0.733

ADAM33-S1c.710 

      

G/A GG

0.905

0.929

0.917

0.932

0.932

0.933

GA

0.095

0.071

0.083

0.068

0.068

0.067

AA

0

0

0

0

0

0

GSDML-236 C/T

      

CC

0.171

0.163

0.167

0.162

0.136

0.200

CT

0.467

0.469

0.500

0.459

0.364

0.600

TT

0.362

0.367

0.333

0.378

0.500

0.200

p-value

     

0.008**

OR (95%CI)

     

0.250 (0.086-0.730)

STAT6-21 C/T b

      

CC

0.428

0.449

0.417

0.459

0.523

0.367

CT

0.486

0.418

0.458

0.405

0.295

0.567

TT

0.086

0.133

0.125

0.135

0.182

0.067

a) Except for IL4-590 and IL4-RP2 (n = 110);

b) Polymorphism not in HWE for mild asthma (p-value = 0.038).

χ2 (or Fisher’s exact test when appropriate) significant p-values and OR (95%CI), using the Madeira reference set as a control, are shown in bold (dominant model).

* Heterozygote model, significant p-values and OR (95%CI) for comparison between mild persistent and moderate-severe persistent; Dominant model, Fisher’s exact test p-value = 0.038, OR (95%CI) 4.667 (0.953-22.851); ** Recessive model, significant p-values and OR (95%CI) for comparison between mild persistent and moderate-severe persistent; Heterozygote model: Fisher’s exact test p-value = 0.039, OR 2.625 (1.011-6.817).

Table 3 shows significant effects for the genotypes IL4-590*CT/TT, IL4-RP2*183253/183183, ADRB2-c.16*AG/AA, and GSDML-236*TT. Specifically, the IL4-590*CT/TT genotypes were significantly more frequent in asthma patients (35.8% vs. 20.0%, χ2 p-value = 0.009; OR 2.222, 95% CI 1.191-4.146), persistent asthma (37.8% vs. 20.0%; χ2 p-value = 0.006; OR 2.433, 95% CI 1.264-4.717), and moderate-severe asthma vs. the reference set (20% vs. 50.0%; χ2 p-value = 0.002; OR 4.000, 95% CI 1.701-9.434). Genotypes IL4-RP2*183253/183183 were significantly more frequent in asthma patients (30.7% vs. 18.2%; χ2 p-value = 0.027; OR 1.984, 95% CI 1.040-3.788), in persistent asthma (33.8% vs. 18.2%; χ2 p-value = 0.013; OR 2.296, 95% CI 1.159-4.547), and in the moderate-severe asthma vs. the reference set (46.7% vs. 18.2%; χ2 p-value = 0.002; OR 3.938, 95% CI 1.657-9.357). ADRB2-c.16*AG was significantly more frequent in moderate-severe asthma vs. mild asthma (66.7% vs. 36.4%, p-value = 0.010, OR 3.500, 95% CI 1.318-9.293) while GSDML-236*TT displays a significant opposite trend (20.0% and 50.0%, respectively in moderate-severe and mild asthma; χ2 p-value = 0.008, 0R 0.250 95% CI 0.086-0.730).

The results described above are corroborated by the allelic counts (Additional file 2) of IL4-590*T, which are significantly higher in asthma patients (19.4%; χ2 p-value = 0.010, OR 2.060, 95% CI 1.178-3.601), in persistent asthma (20.3% χ2 p-value = 0.009, OR 2.178 95% CI 1.208-3.925), and in moderate-severe (28.3%, χ2 p-value = 4.514*10-4, OR 3.386 95% CI 1.668-6.877) vs. the reference set (10.5%). Similarly, the allelic counts of IL4-RP2*183 were significantly higher in moderate-severe vs. the reference set (26.7% vs. 10.5%; χ2 p-value = 0.001, OR 3.115 95% CI 1.521-6.379).

SNP association to FEV1 and FVC

Table 4 shows the association analysis of SNP genotypes with the FEV1 and FVC indexes. Significant differences were found for mean FEV1 distribution among IL4-590*C/T genotypes (F = 3.982, p-value = 0.024), with IL4-590*CT/TT patients exhibiting a significantly lower FEV1 values when compared to IL4-590*CC homozygotes patients (t = 2.797, p-value = 0.006). Similarly, a significantly lower FEV1 index was found amongst patients with IL4-RP2*183253/183183 when compared to IL4-RP2*253253 homozygotes (t = 2.974, p-value = 0.004).
Table 4

Mean FEV 1 and FVC indexes across SNP genotypes

SNP genotypes

Lung function indexes

 

FEV1(mean +/-s.d.)

FVC (mean+/-s.d.)

n

98

98

IL13-c.144 G/A

GG

98.42 + -13.95

96.33 + -11.88

 

GA

93.44 + -16.58

92.15 + -14.79

 

AA

92.50 + -7.78

89.50 + -12.02

IL4-590 C/T

CC

99.92 + -14.28

96.87 + -11.28

 

CT

91.69 + -14.41

92.13 + -14.79

 

TT

90.00 + -12.00

87.67 + 16.04

F p-value

0.024

 

Dominant model CT/TT vs CC

0.006

 

IL4-RP2 253/183

253253

99.75 + -14.15

97.07 + -11.34

 

183253

90.59 + -14.52

90.74 + -14.89

 

183183

90.00 + -12.00

87.67 + -16.04

F p-value

0.015

 

Dominant model 183253/183183 vs 253253

0.004

 

ADRB2-c.16 A/G

AA

95.16 + -19.79

91.74 + -16.20

 

AG

95.91 + -12.83

94.91 + -11.95

 

GG

99.47 + -13.94

97.19 + -11.62

ADAM33-V4 C/G

GG

99.00 + -0 c

98.00 + -0c

 

CG

94.65 + -15.66

94.26 + -10.19

 

CC

97.61 + -14.53

95.24 + -13.61

ADAM33-S1c.710 G/A

GG

97.13 + -14.81

95.22 + -13.05

 

GA

94.29 + -13.96

92.71 + -8.92

 

AA

-

-

GSDML-236 C/T

CC

99.13 + -13.20

94.25 + -12.07

 

CT

96.30 + -17.48

94.13 + -14.34

 

TT

96.75 + -11.34

96.56 + -11.04

STAT6-21 C/T

CC

97.34 + -15.74

95.00 + -14.28

 

CT

96.49 + -13.52

94.24 + -11.73

 

TT

96.92 + -15.73

97.69 + -11.01

c n = 1.

A Shapiro-Wilkoxon test showed that FEV1 is normally distributed (p > 0.05) while FVC is not (p = 0.008). Thus, ANOVA was used for FEV1 analysis while a Kruskal-Wallis test was used for FVC.

SNP association to SPT

Despite not associated to SPT positivity, some of the studied SNPs relate to the sensitization degree (Table 5). ADAM33-V4*CC relates to house dust mite (Dermatophagoides pteronyssinus χ2 p-value = 0.016, OR 1.325, 95% CI 1.070-1.641 and Blomia tropicalis χ2 p-value = 0.047, OR 1.355, 95% CI 1.131-1.622). STAT6-21*TT is associated to the degree of sensitization for storage mite (χ2 p-value = 0.003, OR 7.778, 95% CI 1.682- 35.962).
Table 5

Skin prick tests positivity across SNP genotypes

Allergen panel

  

SNP genotypes

  
   

ADAM33-V4 C/G

  
  

n

GG

CG

CC

p-value

OR (95% CI)

Dermatophagoides pteronyssinus

(-)

23

0.043

0.348

0.609

  

(+)

74

0

0.203

0.797

  
 

< 10 mm

44

0

0.295

0.705

  
 

≥ 10 mm

30

0

0.067

0.933

0.016

1.325 (1.070-1.641)

Blomia tropicalis

(-)

43

0.023

0.279

0.698

  
 

(+)

54

0

0.204

0.796

  
 

< 10 mm

42

0

0.262

0.738

  
 

≥ 10 mm

12

0

0

1.00

0.047

1.355 (1.131-1.622)

   

STAT6-21 C/T

  
   

CC

CT

TT

  

Storage mites

(-)

53

0.396

0.472

0.132

  
 

(+)

44

0.500

0.364

0.236

  
 

< 10 mm

35

0.514

0.429

0.057

  
 

≥ 10 mm

9

0.444

0.111

0.444

0.003*

7.778 (1.682-35.962)

Only significant associations are reported, in bold.

Storage mites: Lepidoglyphus destructor, Glycifagus domesticus, Acarus siro, Euroglyphus maynei and Tyrophagus putrescentiae allergens, classified as ≥ 10 mm if at least one test resulted in wheal diameter ≥ 10 mm.*Recessive model.

SNP haplotypes and epistasis association to asthma risk

Table 6 shows the haplotype frequencies for SNPs at the 5q31 and 20p13 chromosomal regions. At the 5q31, we highlight IL4-590/IL4-RP2* T183 frequency, which is significantly lower in the reference set (8.8%) than overall asthma (16.8%, p-value = 0.019), persistent asthma (18.2%, p-value = 0.011), and moderate-severe asthma (26.7%, p-value = 3×10-4). In addition, this same haplotype was more common in moderate-severe vs. mild asthma (26.7% vs. 12.5%, p-value = 0.029). In fact, every haplotype found to associate with the risk of asthma includes either IL4-590 C/T or IL4-RP2183/253 or both. Compared to the reference set, the most significant combinations are i) overall asthma IL13c.144/IL4-590*GT (p-value = 0.018); ii) persistent asthma IL13c.144/IL4-590*GT (p-value = 0.010) and iii) moderate-severe asthma IL4-590/IL4-RP2*T183 (p-value = 3x10-4). IL13c.144/IL4-RP2*A183 is also more frequently found in moderate-severe asthma than in mild asthma (p-value = 0.017).
Table 6

SNP haplotype frequencies in the Madeira reference set and the asthmatics study population

Haplotype block

 

Study sample set

  

Madeira reference set

Overall asthma

Intermittent asthma

Persistent asthma

Mild

Moderate-severe

 

105a

98

24

74

44

30

IL4-590/ IL4-RP2

T183

0.088

0.168 (0.019)

0.125

0.182 (0.011)

0.125

0.267 (3x10 -4 /0.029*)

 

C253

0.894

0.806

0.833

0.797

0.852

0.717 (0.004/0.044*)

IL4-590 /ADRB2-c.16

TA

0.018

0.058 (0.037)

0.064

0.055 (0.048)

0.031

0.085 (0.009)

 

TG

0.092

0.136

0.102

0.148

0.117

0.199 (0.023)

IL4-RP2/ADRB2-c.16

183A

0.025

0.057

0.059

0.056

0.032

0.089 (0.026)

 

183G

0.084

0.111

0.066

0.127

0.093

0.178 (0.037)

IL13-c.144/ IL4-590

GT

0.064

0.134 (0.018)

0.098

0.146 (0.010)

0.128

0.166 (0.010)

 

AT

0.046

0.060

0.068

0.057

0.020

0.110 (0.020*)

IL13-c.144/ IL4-RP2

G183

0.059

0.106

0.052

0.124 (0.033)

0.105

0.147 (0.022)

 

A183

0.050

0.063

0.073

0.059

0.021

0.114 (0.017*)

IL13-c.144/ IL4-590/ IL4-RP2

GT183

0.051

0.107 (0.041)

0.054

0.125 (0.016)

0.105

0.148 (0.009)

 

AT183

0.040

0.062

0.071

0.058

0.020

0.119 (0.024/0.018*)

IL4-590/ IL4-RP2/ ADRB2-c.16

T183A

0.016

0.055 (0.038)

0.052

0.053 (0.045)

0.030

0.082 (0.008)

 

T183G

0.073

0.113

0.067

0.129

0.095

0.184 (0.013)

Haplotypes denoting significant differences are shown in bold, with respective p-values within parentheses. Significant p-values, using Madeira reference set as a control, are shown within parentheses; * significant p-values for comparison between mild persistent and moderate-severe persistent.

Epistatic interactions between pairs of SNPs between all asthma subgroups were tested, revealing significant epistasis for loci IL4-590 and STAT6-21 in moderate-to-severe compared to intermittent asthma (p-value = 0.044) and IL13-c.144 and ADAM33-V4 between persistent asthma and the Madeira reference set (p-value = 0.035).

TDT association analysis

The TDT analysis in Table 7 suggests that the ADAM33-V4*C allele is significantly over transmitted to offsprings in overall asthma (ratio 27/15 of transmitted/non-transmitted; McNemar χ2 3.429, p-value = 0.044, OR 1.800, 95% CI 0.956-3.384), in persistent asthma (ratio 22/9 of transmitted/non-transmitted; McNemar χ2 5.452, p-value = 0.015 OR 2.444, 95% CI 1.126-5.309), and in mild asthma (ratio 16/4 of transmitted/non-transmitted; McNemar χ2 7.200 p-value = 0.006 OR 4.000, 95% CI 1.337-11.965). IL4-590*T and IL4-RP2*183 alleles were found to be significantly over transmitted only amongst moderate-severe offspring asthma (ratio 15/6 of transmitted/non-transmitted; McNemar χ2 3.857, p-value = 0.039 OR 2.500, 95% CI 0.970-6.443 and ratio 14/4 of transmitted/non-transmitted; McNemar χ2 5.556, p-value = 0.015 OR 3.500, 95% CI 1.152-10.663, respectively).
Table 7

TDT analysis in family trios for SNP association with asthma

SNP allele

Valid trios (n)

TDT-test value

TDT p-value

OR (95% CI)

Overall asthma

    

ADAM33-V4*C

41

3.429

0.044

1.800 (0.956-3.384)

Persistent asthma

    

ADAM33-V4*C

30

5.452

0.015

2.444 (1.126-5.309)

Mild asthma

    

ADAM33-V4*C

19

7.200

0.006

4.000 (1.337-11.965)

Moderate-severe asthma

    

IL4-590*T

19

3.857

0.039

2.500 (0.970-6.443)

IL4-RP2*183

17

5.556

0.015

3.500 (1.152-10.633)

Only significant associations are reported, in bold.

Discussion

In the asthmatic patients studied, 24.5% are classified as intermittent asthmatics while the remaining are persistent asthmatics (of which 40.5% show moderate-severe forms of the disease). The significant differences we observed for FEV1 and FVC indexes denote these as reliable indicators for disease severity, as previous stated by a number of studies [48–50].

SNP IL4-590 C/T has been repeatedly associated to asthma in several population backgrounds [17–22] and the results of this study in the Madeira island population are no exception (previously reported by our research team [7]. Our findings show that IL4-590*CT/TT genotypes associate to a 2.2-fold risk for asthma (2.4-fold for overall persistent asthma and 4-fold for moderate-severe persistent asthma) while IL4-590*T allele represents a 2-fold risk for asthma (2.2-fold for persistent asthma and 3.4-fold for moderate-severe asthma), compared to individuals harbouring other IL4-590 C/T genotypes or allele. Our findings also indicate that IL4-RP2*253183/183183 genotypes translate into a 2-fold increased risk for asthma (2.3-fold and 2.9-fold respectively for persistent and moderate-severe persistent asthma), in particular IL4-RP2*183 allele (3.1-fold risk for moderate-severe persistent asthma). This SNP has been implicated in childhood asthma in a Chinese population, where authors suggest a link between the allele and higher expression of IL4 in asthma [24]. The findings for IL4 SNPs are further corroborated by the association of the risk genotypes to worse lung function, namely lower FEV1 index. Genotype IL4-590*TT has been previously associated with lower FEV1 index, used as a measure for asthma severity, in a population of white asthmatic subjects [51].

IL4 is a key cytokine in IgE production via Th2 pathway [52], which has been previously shown to play an important role in asthma pathogenesis [53]. Its serous levels are significantly higher in steroid-naive asthmatic children and severe forms of asthma when compared to healthy control groups [54, 55]. From a functional perspective, it is not surprising that IL4 SNPs may regulate its transcription rates: allele IL4-590*T allows an extra binding site for the nuclear factor of activated T-cells (NFAT) at IL4 promoter, leading to a 3-fold higher transcription rate [23]; haplotypes with IL4-RP2*183 and SNPs within IL4 promoter account for high IL4 expression [56].

The case–control associations of IL4-590*T and IL4-RP2*183 to moderate-severe persistent asthma are further corroborated by TDT analysis (2.5 and 3.5-fold increased risk respectively). TDT is a family-based test robust against population stratification [57, 58] defined as the presence of multiple subgroups with distinct allele frequencies within a population [59]. Although stratification is mostly noticed in recent history of admixture [60], we cannot disregard the considerable sub-Saharan and northern African proportion in the Madeira genetic background, due to the North Atlantic slavetrade on the 16th-19th centuries and previously confirmed by Y-chromosome [61] and mtDNA studies [62].

Previous studies have related ADRB2-c.16*GG to asthma onset and severity [25, 26]. Conversely, our data suggest heterozygous ADRB2-c.16*AG as 3.5-fold risk genotype for moderate-severe asthma. In the absence of functional studies, we can only hypothesize that heterodimeric ADRB2 receptors on the bronchial smooth muscle may be less stable or bind to a more restricted scope of products than homodimeric receptors, therefore enhancing more severe forms of asthma. However, the high heterozygosity for ADRB2-c.16 is found not only in patient’s subgroups but also in the Madeira reference set and other population sets [63–65]. Even though it deserves more attention, this may indicate heterozygote advantage for this SNP or other in linkage disequilibrium, in a metabolic pathway that may or may not relate to asthma pathogenesis. Other examples of heterozygote advantage in ADRB2 exist, such as ADRB2-c.27*CG that is protective against lung function decline [66] and accounts for a decreased risk of asthma [67].

In our data, GSDML-236*TT genotype is found to be a protective for asthma severity, with a 4-fold significantly lower frequency in moderate-severe asthma, as opposed to mild. GSDML-236C/T polymorphism has been related to asthma predisposition, severity and/or asthma-related phenotypes in a number of studies [31–39]. However, our results are in contrast to certain previous studies, which suggest this genotype is a genetic risk factor for the disease severity [32, 35, 37, 38]. The GSDML encodes for gasdermin B protein expressed in epithelial barrier function and skin differentiation, influencing the expression of the neighbouring gene ORMDL3 and thus contributing to asthma susceptibility [34].

The case–control association in our dataset does not support the influence of ADAM33-V4C/G or ADAM33-S1c.710G/A in asthma, contrary to some previous work [27–30] and consistent with other studies [68]. ADAM33-V4*C allele was nevertheless marginally over transmitted to Madeira asthmatics, as suggested by TDT analysis (1.8-fold risk for overall asthma, 2.4-fold risk for persistent asthma and 4-fold risk for mild asthma). A similar trend of association was seen in Caucasian children with asthma and bronchial responsiveness (p-value = 0.0959) [27]. Located at 3’-UTR, ADAM33-V4C/G SNP may influence the expression of its encoded desintegrin and metallopeptidase domain 33 in airway smooth muscle and lung fibroblasts [27, 69, 70] thus playing a role on airway remodeling and bronchial responsiveness [27, 71]. In addition, our study associates ADAM33-V4*CC to a wheal size ≥ 10 mm both in Dermatophagoides pteronyssinus and Blomia tropicalis, in accordance with a previous study relating ADAM33-V4*CC to high levels of IgE against Blomia tropicalis (Z score: 2.089, p = 0.03) [72].

No significant association with the disease risk was detected for STAT6-21C/T, similar to the analysis in [73] but contrary to other studies [19, 40–44]. However, STAT6-21*TT is overrepresented in asthmatics with a ≥10 mm wheal size reaction to storage mites and shows a significant epistatic interaction with IL4-590C/T between moderate-severe persistent and intermittent asthma. The enhanced allergic response is not unexpected since STAT6 is a signal transducer and activator of transcription enrolled in the regulation of IgE expression [40, 52, 74] whose STAT6-21*T allele promotes higher levels of IgE [19].

Finally, the haplotype analysis was significant for SNPs at 5q31, namely IL4-590*T and IL4-RP2*183 in overall asthma, persistent asthma and moderate-severe persistent asthma. Haplotypes of IL4-RP2*183 and SNPs within the promoter of IL4 have been found to account for high IL4 expression [56]. Our results also indicate the synergistic effect of IL13c.144*G and ADRB2*G with either IL4-590*T or IL4-RP2*183 or both for the onset of asthma persistent phenotypes. Nevertheless, their combination equals or slightly lowers the statistical significance of IL4-590/IL4-RP2*T183 haplotype in the same classes.

Conclusion

In conclusion, this study has replicated previously reported genetic associations and brought light to new associations of polymorphisms, individually or in haplotype, to asthma susceptibility, persistence and/or severity in the Madeira island population. IL4-590C/T and IL4-RP2253/183 seem to play an important role in the development of the disease, especially its moderate-severe persistent forms, as demonstrated by allele and haplotype case–control tests, TDT analysis, and significantly poorer FEV1 index. GSDML*CT/TT and ADRB2c.16*AG are found to predict asthma severity in case–control association, respectively as risk and protective factors for moderate-severe forms. ADAM33-V4*C and STAT-21*TT seem to enhance the allergic response to Dermatophagoides pteronyssinus and Blomia tropicalis and to storages mites, respectively, and the first is further highlighted by TDT analysis as a risk factor for mild persistent asthma. The combined genotyping of IL4-590C/T, IL4-RP2-253/183, GSDML-236C/T and ADAM33-V4C/G could be of clinical relevance in ascertaining the risk of asthma onset and/or its persistence and severity, thus helping to define appropriate strategies for asthma healthcare in this island.

Methods

Participants

A sample of 98 atopic asthmatics, aged between 6 and 25 years old, and their parents (fathers n = 88 and mothers n = 96) were recruited at the Immunoalergology Unit, Dr. Nélio Mendonça Hospital, in Funchal, Madeira. For all participants, the last three generations of ancestors were born and lived in Madeira island. The diagnosis of asthma was based on clinical criteria associated with lung function and the SPT. For the epidemiologic characterization we deployed the ISAAC questionnaire to the asthmatic population and their parents. Following the GINA guidelines [75], pattern and frequency of symptoms associated with lung function were used to classify asthma into intermittent (n = 24) and persistent (n = 74), and the severity in persistent asthma was further classified as mild (n = 44), moderate (n = 26) and severe (n = 4). Given the small number of patients, the moderate and severe subgroups were merged. Asthma induced by exercise and associated to aspirin was excluded.

Ethics statement

The study had the approval of the Ethics Committee of Dr. Nélio Mendonça Hospital and the informed consent of the participants.

Allergy profile

The SPT was tested for an optimized battery with the most common aeroallergens in this island: house dust mite (Dermatophagoides pteronyssinus, Blomia tropicalis); storage mite (Lepidoglyphus destructor, Glycyphagus domesticus, Acarus siro, Euroglyphus maynei, Tyrophagus putrescentiae); Mix fungi (Fungus I, Fungus II); indoor fungi (Aspergillus fumigatus, Mucor sp.) and cat and dog. STP results were interpreted according to mean wheal size: positive ≥3 mm, sensitization degree ≤10 mm or ≥10 mm.

DNA extraction and genotyping

Patients’ blood samples were collected by venipuncture in 8 ml EDTA blood collection tubes and their DNA was extracted by salting-out method (adapted from [76]). Their parents contributed with saliva samples, collected in Oragene•DNA (OG-250) kits (Oragene). The DNA extraction followed the manufacturer’s instructions.

A sample of 110 unrelated individuals, whose ancestry was of local origin for the last three generations, was obtained from the Blood Sample Bank of Human Genetics Laboratory (LGH) and their DNA extraction was performed by a standard phenol-chloroform protocol (adapted from [77]). These constitute the Madeira population reference sample set, although their disease status is unknown. The reference sample set was not matched to the patient’s group to uphold a less biased study design. Each SNP (Table 1) was analysed by TaqMan real-time PCR (Applied Biosystems) according to the manufacturer’s instructions, in a 7300 System SDS Software v1.4.

Statistical analysis

The statistical analysis was performed using SPSS (IBM SPSS Statistics, version 19.0.0), except for the Hardy-Weinberg Equilibrium (HWE) for each polymorphism, determined in ARLEQUIN version 3.11 [78]. Gender and SPT data among subgroups of asthma persistence and severity were analysed using Fisher’s exact test, to account for the small sample size.

Following a Shapiro-Wilkoxon test of normality, the association analysis of FEV1 to asthma persistence and severity was performed using a t-test (normal distribution), while a Mann–Whitney test was used for FVC (due to its non-normal distribution). The analysis of FEV1 and FVC indexes among SNP genotypes was tested using ANOVA (with Bonferroni post-hoc correction) and Kruskal-Wallis test, respectively.

The association of SNP genotypes and alleles to asthma susceptibility and severity, for multiple genetic models, were assessed by χ2 (or Fisher’s exact tests where appropriate) and corresponding odds ratio (OR) determined with a 95% CI. Haplotypes were generated with Haploview version 4.2 [79] and their association with the disease was analysed with the hap-assoc option in PLINK [80]. Epistatic interactions between pairs of SNPs were assessed with the PLINK option --epistasis --epi1 1. Permutation procedures were used to obtain significance levels empirically and results were interpreted at a significance level set for p < 0.05.

The transmission disequilibrium test (TDT) was determined through a McNemar test [81], based on data from heterozygous parents and the frequency of allelic transmission to affected offspring. The corresponding p-value (considered at a 0.05 significance level) and OR (95% CI) were determined.

To reduce the likelihood of commiting a Type I error due to multiple testing, the Benjamini & Hochberg procedure [82] was adopted for each set of results (presented in distinct tables) to control the false discovery rate set at Q = 0.20.

Notes

Abbreviations

ADAM33: 

A Disintegrin and Metalloprotease 33

ADRB2: 

Beta-2-adrenergic receptor

FEV1: 

Forced Expiratory Volume in 1 second

FVC: 

Forced Vital Capacity

GINA: 

Global Initiative for Asthma

GSDML: 

Gasdermin-like

IL4: 

Interleukin 4

IL13: 

Interleukin 13

SNPs: 

Single Nucleotide Polymorphisms

SPT: 

Skin Prick Tests

STAT6: 

Signal Transducer and Activator of Transcription 6 (STAT6)

TDT: 

Transmission Disequilibrium Test.

Declarations

Acknowledgements

This project had the financial support of FEDER within the framework of the INTERREGIII C program. Anabela Berenguer is a recipient of a PhD scholarship from Fundação para a Ciência e Tecnologia (FCT) with the reference SFRH/BD/31273/2006. Ph.D. Ana Teresa Fernandes passed away during the course of the project.

Authors’ Affiliations

(1)
Human Genetics Laboratory, University of Madeira, Funchal, 9000-390, Portugal
(2)
Immunoalergology Unit, Dr. Nélio Mendonça Hospital, SESARAM, E.P.E, Funchal, Portugal
(3)
Unit of Statistics, Dr. Nélio Mendonça Hospital, SESARAM, E.P.E, Funchal, Portugal
(4)
Medical Sciences Unit, Center of Life Sciences, University of Madeira, Funchal, 9000-390, Portugal
(5)
Department of Computer Science and Engineering, University of Oulu, PL 4500, Oulu, 90014, Finland

References

  1. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, de Jongste JC, Kerstjens HA, Lazarus SC, Levy ML, O’Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW, Sullivan SD, Szefler SJ, Thomas MD, Wenzel SE, American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations: An official american thoracic society/european respiratory society statement: asthma control and exacerbations. Am J Respir Crit Care Med 2009, 180(Suppl1):59-99.View ArticlePubMedGoogle Scholar
  2. Cookson WOC: Asthma genetics. Chest 2002, 121(Suppl 3):7-13.View ArticleGoogle Scholar
  3. Su MW, Tung KY, Liang PH, Tsai CH, Kuo NW, Lee YL: Gene-gene and gene-environmental interactions of childhood asthma: a multifactor dimension reduction approach. PLoS One 2012, 7(Suppl 2):e30694.PubMed CentralView ArticlePubMedGoogle Scholar
  4. Samolinski B, Fronczak A, Kuna P, Akdis CA, Anto JM, Bialoszewski AZ, Burney PG, Bush A, Czupryniak A, Dahl R, Flood B, Galea G, Jutel M, Kowalski ML, Palkonen S, Papadopoulos N, Raciborski F, Sienkiewicz D, Tomaszewska A, Von Mutius E, Willman D, Włodarczyk A, Yusuf O, Zuberbier T, Bousquet J, Niggemann B: Prevention and control of childhood asthma and allergy in the EU from the public health point of view: an urgent need to fill the gaps. Allergy 2012, 67(Suppl 6):726-731.PubMed CentralView ArticlePubMedGoogle Scholar
  5. To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, Boulet LP: Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health 2012, 12: 204. 10.1186/1471-2458-12-204PubMed CentralView ArticlePubMedGoogle Scholar
  6. Pinto JR, Almeida MM: Epidemiology of asthma in schoolchildren in Portuguese speaking regions. Rev Fr Allergol 2005, 45: 547-549.Google Scholar
  7. Berenguer AG, Câmara RA, Brehm AD, Oliveira S, Fernandes AT: Distribution of polymorphisms IL4-590 C/T and IL4-RP2 in the human populations of Madeira, Azores, Portugal, Cape Verde and Guinea-Bissau. Int J Mol Epidemiol Genet 2012, 3(Suppl 2):179-183.PubMed CentralPubMedGoogle Scholar
  8. von Mutius E: Gene-environment interactions in asthma. J Allergy Clin Immunol 2009, 123(Suppl 1):3-11.View ArticlePubMedGoogle Scholar
  9. Vercelli D: Discovering susceptibility genes for asthma and allergy. Nat Rev Immunol 2008, 8(Suppl 3):169-182.View ArticlePubMedGoogle Scholar
  10. Heinzmann A, Mao X-Q, Akaiwa M, Kreomer RT, Gao P-S, Ohshima K, Umeshita R, Abe Y, Braun S, Yamashita T, Roberts MH, Sugimoto R, Arima K, Arinobu Y, Yu B, Kruse S, Enomoto T, Dake Y, Kawai M, Shimazu S, Sasaki S, Adra CN, Kitaichi M, Inoue H, Yamauchi K, Tomichi N, Kurimoto F, Hamasaki N, Hopkin JM, Izuhara K, et al.: Genetic variants of IL-13 signalling and human asthma and atopy. Hum Mol Genet 2000, 9(Suppl 4):549-559.View ArticlePubMedGoogle Scholar
  11. Chen W, Ericksen MB, Levin LS, Hershey GK: Functional effect of the R110Q IL13 genetic variant alone and in combination with IL4RA genetic variants. J Allergy Clin Immunol 2004, 114(Suppl 3):553-560.View ArticlePubMedGoogle Scholar
  12. Vladich FD, Brazille SM, Stern D, Peck ML, Ghittoni R, Vercelli D: IL-13 R130Q, a common variant associated with allergy and asthma, enhances effector mechanisms essential for human allergic inflammation. J Clin Invest 2005, 115(Suppl 3):747-754.PubMed CentralView ArticlePubMedGoogle Scholar
  13. Bottema RW, Nolte IM, Howard TD, Koppelman GH, Dubois AE, de Meer G, Kerkhof M, Bleecker ER, Meyers DA, Postma DS: Interleukin 13 and Interleukin 4 Receptor-alpha Polymorphisms in Rhinitis and Asthma. Int Arch Allergy Immunol 2010, 153(Suppl 3):259-267.View ArticlePubMedGoogle Scholar
  14. Brightling CE, Saha S, Hollins F: Interleukin-13: prospects for new treatments. Clin Exp Allergy 2010, 40(Suppl 1):42-49.PubMed CentralPubMedGoogle Scholar
  15. Chu Y, Hua L, Liu Q, Bao Y: A common variant associated with asthma, interleukin 13 R130Q, promotes the production of IgE. Int J Immunogenet 2012, 39(Suppl 4):308-313.View ArticlePubMedGoogle Scholar
  16. Cui L, Jia J, Ma C-F, Li S-Y, Wang Y-P, Guo X-M, Li Q, Yu H-B, Liu W-H, Gao LB: IL-13 polymorphisms contribute to the risk of asthma: a meta-analysis. Clin Biochem 2012, 45(Suppl 4–5):285-288.View ArticlePubMedGoogle Scholar
  17. Wang W, Halmurat W, Yilihamu S, Xiang YB, Ablikemu A: A study on the relationship between interleukin-4 promoter polymorphism and asthma in a Xinjiang Uyger population. Zhonghua Jie He He Hu Xi Za Zhi 2004, 27(Suppl 7):460-464.PubMedGoogle Scholar
  18. Gervaziev YV, Kaznacheev VA, Gervazieva VB: Allelic polymorphisms in the interleukin-4 promoter regions and their association with bronchial asthma among the Russian population. Int Arch Allergy Immunol 2006, 141(Suppl 3):257-264.View ArticlePubMedGoogle Scholar
  19. Kabesch M, Schedel M, Carr D, Woitsch B, Fritzsch C, Weiland SK, von Mutius E: IL-4/IL-13 pathway genetics strongly influence serum IgE levels and childhood asthma. J Allergy Clin Immunol 2006, 117(Suppl 2):269-274.View ArticlePubMedGoogle Scholar
  20. Chiang CH, Tang YC, Lin MW, Chung MY: Association between the IL-4 promoter polymorphisms and asthma or severity of hyperresponsiveness in Taiwanese. Respirology 2007, 12(Suppl 1):42-48.View ArticlePubMedGoogle Scholar
  21. de Guia RM, Ramos JD: The -590C/T IL4 single-nucleotide polymorphism as a genetic factor of atopic allergy. Int J Mol Epidemiol Genet 2010, 1(Suppl 1):67-73.PubMed CentralPubMedGoogle Scholar
  22. Li Y, Guo B, Zhang L, Han J, Wu B, Xiong H: Association between C-589T polymorphisms of interleukin-4 gene promoter and asthma: a meta-analysis. Respir Med 2008, 102(Suppl 7):984-992.View ArticlePubMedGoogle Scholar
  23. Rockman MV, Hahn MW, Soranzo N, Goldstein DB, Wray GA: Positive selection on a human-specific transcription factor binding site regulating IL4 expression. Curr Biol 2003, 13(Suppl 23):2118-2123.View ArticlePubMedGoogle Scholar
  24. Fang GF, Fan XY, Shen FH: The relationship between polymorphisms of interleukin­4 gene and silicosis. Biomed Environ Sci 2011, 24(Suppl 6):678-682.PubMedGoogle Scholar
  25. Sato R: The role of beta 2-adrenoceptor gene polymorphisms in asthma. Hokkaido Igaku Zasshi 2000, 75(Suppl 2):81-94.PubMedGoogle Scholar
  26. Contopoulos-Ioannidis DG, Manoli EN, Ioannidis JPA: Meta-analysis of the association of b2- adrenergic receptor polymorphisms with asthma phenotypes. J Allergy Clin Immunol 2005, 115(Suppl 5):963-972.View ArticlePubMedGoogle Scholar
  27. Eerdewegh PV, Little RD, Dupuis J, Del Mastro RG, Falls K, Simon J, Torrey D, Pandit S, McKenny J, Braunschweiger K, Walsh A, Liu Z, Hayward B, Folz C, Manning SP, Bawa A, Saracino L, Thackston M, Benchekroun Y, Capparell N, Wang M, Adair R, Feng Y, Dubois J, FitzGerald MG, Huang H, Gibson R, Allen KM, Pedan A, Danzig MR, et al.: Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 2002, 418(Suppl 6896):426-430.View ArticlePubMedGoogle Scholar
  28. Howard TD, Postma DS, Jongepier H, Moore WC, Koppelman GH, Zheng SL, Xu J, Bleecker ER, Meyers DA: Association of a disintegrin and metalloprotease 33 (ADAM33) gene with asthma in ethnically diverse populations. J Allergy Clin Immunol 2003, 112(Suppl 4):717-722.View ArticlePubMedGoogle Scholar
  29. Su D, Zhang X, Sui H, Lü F, Jin L, Zhang J: Association of ADAM33 gene polymorphisms with adult allergic asthma and rhinitis in a Chinese Han population. BMC Med Genet 2008, 9: 82.PubMed CentralView ArticlePubMedGoogle Scholar
  30. Qu S, Sun D, Wang Y, Zhang C, Lv Y, Yao L: Association of ADAM33 polymorphisms with childhood asthma in a northern Chinese population. Exp Mol Pathol 2011, 91(Suppl 3):775-779.View ArticlePubMedGoogle Scholar
  31. Moffatt MF, Kabesch M, Liang L, Dixon AL, Strachan D, Heath S, Depner M, von Berg A, Bufe A, Rietschel E, Heinzmann A, Simma B, Frischer T, Willis-Owen SA, Wong KC, Illig T, Vogelberg C, Weiland SK, von Mutius E, Abecasis GR, Farrall M, Gut IG, Lathrop GM, Cookson WO: Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 2007, 448(Suppl 7152):470-473.View ArticlePubMedGoogle Scholar
  32. Galanter J, Choudhry S, Eng C, Nazario S, Rodríguez-Santana JR, Casal J, Torres-Palacios A, Salas J, Chapela R, Watson HG, Meade K, LeNoir M, Rodríguez-Cintrón W, Avila PC, Burchard EG: ORMDL3 gene is associated with asthma in three ethnically diverse populations. Am J Respir Crit Care Med 2008, 177(Suppl 11):1194-1200.PubMed CentralView ArticlePubMedGoogle Scholar
  33. Madore AM, Tremblay K, Hudson TJ, Laprise C: Replication of an association between 17q21 SNPs and asthma in a French-Canadian familial collection. Hum Genet 2008, 123(Suppl 1):93-95.View ArticlePubMedGoogle Scholar
  34. Tavendale R, Macgregor DF, Mukhopadhyay S, Palmer CN: A polymorphism controlling ORMDL3 expression is associated with asthma that is poorly controlled by current medications. J Allergy Clin Immunol 2008, 121(Suppl 4):860-863.View ArticlePubMedGoogle Scholar
  35. Bisgaard H, Bønnelykke K, Sleiman PM, Brasholt M, Chawes B, Kreiner-Møller E, Stage M, Kim C, Tavendale R, Baty F, Pipper CB, Palmer CN, Hakonarsson H: Chromosome 17q21 gene variants are associated with asthma and exacerbations but not atopy in early childhood. Am J Respir Crit Care Med 2009, 179(Suppl 3):179-185.View ArticlePubMedGoogle Scholar
  36. Wu H, Romieu I, Sienra-Monge JJ, Li H, del Rio-Navarro BE, London SJ: Genetic variation in ORM1-like 3 (ORMDL3) and gasdermin-like (GSDML) and childhood asthma. Allergy 2009, 64(Suppl 4):629-635.PubMed CentralView ArticlePubMedGoogle Scholar
  37. Halapi E, Gudbjartsson DF, Jonsdottir GM, Bjornsdottir US, Thorleifsson G, Helgadottir H, Williams C, Koppelman GH, Heinzmann A, Boezen HM, Jonasdottir A, Blondal T, Gudjonsson SA, Jonasdottir A, Thorlacius T, Henry AP, Altmueller J, Krueger M, Shin HD, Uh ST, Cheong HS, Jonsdottir B, Ludviksson BR, Ludviksdottir D, Gislason D, Park CS, Deichmann K, Thompson PJ, Wjst M, Hall IP, et al.: A sequence variant on 17q21 is associated with age at onset and severity of asthma. Eur J Hum Genet 2010, 18(Suppl 8):902-908.PubMed CentralView ArticlePubMedGoogle Scholar
  38. Binia A, Khorasani N, Bhavsar PK, Adcock I, Brightling CE, Chung KF, Cookson WO, Moffatt MF: Chromosome 17q21 SNP and severe asthma. J Hum Genet 2011, 56(Suppl 1):97-98.PubMed CentralView ArticlePubMedGoogle Scholar
  39. Yu J, Kang MJ, Kim BJ, Kwon JW, Song YH, Choi WA, Shin YJ, Hong SJ: Polymorphisms in GSDMA and GSDMB are associated with asthma susceptibility. Atopy and BHR. Pediatr Pulmonol 2011, 46(Suppl 7):701-708.View ArticlePubMedGoogle Scholar
  40. Schedel M, Carr D, Klopp N, Woitsch B, Illig T, Stachel D, Schmid I, Fritzsch C, Weiland SK, von Mutius E, Kabesch M: A signal transducer and activator of transcription 6 haplotype influences the regulation of serum IgE levels. J Allergy Clin Immunol 2004, 114(Suppl 5):1100-1105.View ArticlePubMedGoogle Scholar
  41. Weidinger S, Klopp N, Wagenpfeil S, Rümmler L, Schedel M, Kabesch M, Schäfer T, Darsow U, Jakob T, Behrendt H, Wichmann HE, Ring J, Illig T: Association of a STAT 6 haplotype with elevated serum IgE levels in a population based cohort of white adults. J Med Genet 2004, 41(Suppl 9):658-663.PubMed CentralView ArticlePubMedGoogle Scholar
  42. Daley D, Lemire M, Akhabir L, Chan-Yeung M, He JQ, McDonald T, Sandford A, Stefanowicz D, Tripp B, Zamar D, Bosse Y, Ferretti V, Montpetit A, Tessier MC, Becker A, Kozyrskyj AL, Beilby J, McCaskie PA, Musk B, Warrington N, James A, Laprise C, Palmer LJ, Paré PD, Hudson TJ: Analyses of associations with asthma in four asthma population samples from Canada and Australia. Hum Genet 2009, 125(Suppl 4):445-459.View ArticlePubMedGoogle Scholar
  43. Schedel M, Frei R, Bieli C, Cameron L, Adamski J, Lauener R, Kabesch M: An IgE-associated polymorphism in STAT6 alters NF-kB binding, STAT6 promoter activity, and mRNA expression. J Allergy Clin Immunol 2009, 124(Suppl 3):583-589.View ArticlePubMedGoogle Scholar
  44. Kavalar MS, Balantic M, Silar M, Kosnik M, Korosec P, Rijavec M: Association of ORMDL3, STAT6 and TBXA2R gene polymorphisms with asthma. Int J Immunogenet 2012, 39(Suppl 1):20-25.View ArticlePubMedGoogle Scholar
  45. Cantagrel A, Navaux F, Loubet-Lescoulié P, Nourhashemi F, Enault G, Abbal M, Constantin A, Laroche M, Mazières B: Interleukin-1beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 1999, 42(Suppl 6):1093-1100.View ArticlePubMedGoogle Scholar
  46. The International HapMap Consortium: The International HapMap Project. Nature 2003, 426: 789-796. 10.1038/nature02168View ArticleGoogle Scholar
  47. Lunetta KL: Statistical primer for cardiovascular research. Circulation 2008, 118: 96-101. 10.1161/CIRCULATIONAHA.107.700401View ArticlePubMedGoogle Scholar
  48. Ramsey CD, Celedón JC, Sredl DL, Weiss ST, Cloutier MM: Predictors of disease severity in children with asthma in Hartford. Connecticut Pediatr Pulmonol 2005, 39(Suppl 3):268-275.View ArticlePubMedGoogle Scholar
  49. Kim TB, Park CS, Bae YJ, Cho YS, Moon HB, COREA Study Group: Factors associated with severity and exacerbation of asthma: a baseline analysis of the cohort for reality and evolution of adult asthma in Korea (COREA). Ann Allergy Asthma Immunol 2009, 103(Suppl 4):311-317.View ArticlePubMedGoogle Scholar
  50. Forno E, Celedón JC: Predicting asthma exacerbations in children. Curr Opin Pulm Med 2012, 18(Suppl 1):63-69.PubMed CentralView ArticlePubMedGoogle Scholar
  51. Burchard EG, Silverman EK, Rosenwasser LJ, Borish L, Yandava C, Pillari A, Weiss ST, Hasday J, Lilly CM, Ford JG, Drazen JM: Association between a sequence variant in the IL-4 gene promoter and FEV1 in asthma. Am J Respir Crit Care Med 1999, 160: 919-922. 10.1164/ajrccm.160.3.9812024View ArticlePubMedGoogle Scholar
  52. Oh CK, Geba GP, Molfino N: Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev 2010, 19(Suppl 115):46-54.View ArticlePubMedGoogle Scholar
  53. Grünig G, Corry DB, Reibman J, Wills-Karp M: Interleukin 13 and the evolution of asthma therapy. Am J Clin Exp Immunol 2012, 1(Suppl 1):20-27.PubMed CentralPubMedGoogle Scholar
  54. Abdulamir AS, Hafidh RR, Abubakar F: Different inflammatory mechanisms in lungs of severe and mild asthma: crosstalk of NF-kappa-B, TGFbeta1, Bax, Bcl-2, IL-4 and IgE. Scand J Clin Lab Invest 2009, 69(Suppl 4):487-495.View ArticlePubMedGoogle Scholar
  55. Lama M, Chatterjee M, Nayak CR, Chaudhuri TK: Increased interleukin-4 and decreased interferon-γ levels in serum of children with asthma. Cytokine 2011, 55(Suppl 3):335-338.View ArticlePubMedGoogle Scholar
  56. Nakashima H, Miyake K, Inoue Y, Shimizu S, Akahoshi M, Tanaka Y, Otsuka T, Harada M: Association between IL-4 genotype and IL-4 production in the Japanese population. Genes Immun 2002, 3(Suppl 2):107-109.View ArticlePubMedGoogle Scholar
  57. Sebro R, Rogus JJ: The power of the Transmission Disequilibrium Test in the presence of population stratification. Eur J Hum Genet 2010, 18(Suppl 9):1032-1038.PubMed CentralView ArticlePubMedGoogle Scholar
  58. Lewis CM: Genetic association studies: design, analysis and interpretation. Brief Bioinform 2002, 3(Suppl 2):146-153.View ArticlePubMedGoogle Scholar
  59. Cardon LR, Bell JI: Association study designs for complex diseases. Nat Rev Genet 2001, 2(Suppl 2):91-99.View ArticlePubMedGoogle Scholar
  60. Freedman ML, Reich D, Penney KL, McDonald GJ, Mignault AA, Patterson N, Gabriel SB, Topol EJ, Smoller JW, Pato CN, Pato MT, Petryshen TL, Kolonel LN, Lander ES, Sklar P, Henderson B, Hirschhorn JN, Altshuler D: Assessing the impact of population stratification on genetic association studies. Nat Genet 2004, 36(Suppl 4):388-393.View ArticlePubMedGoogle Scholar
  61. Gonçalves R, Freitas A, Branco M, Rosa A, Fernandes AT, Zhivotovsky LA, Underhill PA, Kivisild T, Brehm A: Y-chromosome Lineages from Portugal, Madeira and Açores Record Elements of Sephardim and Berber Ancestry. Ann Hum Genet 2005, 69(Suppl 4):443-454.View ArticlePubMedGoogle Scholar
  62. Brehm A, Pereira L, Kivisild T, Amorim A: Mitochondrial portraits of the Madeira and Açores archipelagos witness different genetic pools of its settlers. Hum Genet 2003, 114(Suppl 1):77-86.View ArticlePubMedGoogle Scholar
  63. Binaei S, Christensen M, Murphy C, Zhang Q, Quasney M: β2-Adrenergic receptor polymorphisms in children with status asthmaticus. Chest 2003, 123(Suppl 3):375.Google Scholar
  64. Santillan AA, Camargo CA Jr, Ramirez-Rivera A, Delgado-Enciso I, Rojas-Martinez A, Cantu-Diaz F, Barrera-Saldaña HA: Association between β2-adrenoceptor polymorphisms and asthma diagnosis among Mexican adults. J Allergy Clin Immunol 2003, 112(Suppl 6):1095-1100.View ArticlePubMedGoogle Scholar
  65. Shachor J, Chana Z, Varsano S, Erlich T, Goldman E, Dror Y, Yakovy I, Navon R: Genetic polymorphisms of the beta-2 adrenergic receptor in Israelis with severe asthma compared to non-asthmatic Israelis. Isr Med Assoc J 2003, 5(Suppl 11):821-824.PubMedGoogle Scholar
  66. Joos L, Weir TD, Connett JE, Anthonisen NR, Woods R, Paré PD, Sandford AJ: Polymorphisms in the ß2 adrenergic receptor and bronchodilator response, bronchial hyperresponsiveness, and rate of decline in lung function in smokers. Thorax 2003, 58(Suppl 8):703-707.PubMed CentralView ArticlePubMedGoogle Scholar
  67. Thakkinstian A, McEvoy M, Minelli C, Gibson P, Hancox B, Duffy D, Thompson J, Hall I, Kaufman J, Leung TF, Helms PJ, Hakonarson H, Halpi E, Navon R, Attia J: Systematic review and meta-analysis of the association between b2-Adrenoceptor polymorphisms and asthma: a huge review. Am J Epidemiol 2005, 162(Suppl 3):201-211.View ArticlePubMedGoogle Scholar
  68. Song GG, Kim JH, Lee YH: Association between ADAM33 S2 and ST+4 polymorphisms and susceptibility to asthma: a meta-analysis. Gene 2013, 524(Suppl 1):72-78.View ArticlePubMedGoogle Scholar
  69. Holloway JW, Yan IA, Holgate ST: Genetics of allergic disease. J Allergy Clin Immunol 2010, 125(Suppl 2):81-94.View ArticleGoogle Scholar
  70. Schedel M, Depner M, Schoen C, Weiland SK, Vogelberg C, Niggemann B, Lau S, Illig T, Klopp N, Wahn U, von Mutius E, Nickel R, Kabesch M: The role of polymorphisms in ADAM33, a disintegrin and metalloprotease 33, in childhood asthma and lung function in two German populations. Respir Res 2006, 7: 91. 10.1186/1465-9921-7-91PubMed CentralView ArticlePubMedGoogle Scholar
  71. Yang Y, Wicks J, Haitchi HM, Powell RM, Manuyakorn W, Howarth PH, Holgate ST, Davies DE: Regulation of A disintegrin and Metalloprotease-33 expression by transforming growth factor-beta. Am J Respir Cell Mol Biol 2012, 46(Suppl 5):633-640.PubMed CentralView ArticlePubMedGoogle Scholar
  72. Vergara CI, Acevedo N, Jiménez S, Martínez B, Mercado D, Gusmão L, Barnes KC, Caraballo L: A Six-SNP haplotype of ADAM33 is associated with asthma in a population of Cartagena, Colombia. Int Arch Allergy Immunol 2010, 152(Suppl 1):32-40.PubMed CentralView ArticlePubMedGoogle Scholar
  73. Duetsch G, Illig T, Loesgen S, Rohde K, Klopp N, Herbon N, Gohlke H, Altmueller J, Wjst M: STAT6 as an asthma candidate gene: polymorphism- screening, association and haplotype analysis in a Caucasian sib-pair study. Hum Mol Genet 2002, 11(Suppl 6):613-621.View ArticlePubMedGoogle Scholar
  74. Nofziger C, Vezzoli V, Dossena S, Schönherr T, Studnicka J, Nofziger J, Vanoni S, Stephan S, Silva ME, Meyer G, Paulmichl M: STAT6 Links IL-4/IL-13 stimulation with pendrin expression in asthma and chronic obstructive pulmonary disease. Clin Pharmacol Ther 2011, 90(Suppl 3):399-405.View ArticlePubMedGoogle Scholar
  75. The Global Initiative for Asthma (GINA) http://www.ginasthma.org/
  76. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16(Suppl 3):1215.PubMed CentralView ArticlePubMedGoogle Scholar
  77. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press; 1989.Google Scholar
  78. Excoffier L, Laval G, Schneider S: Arlequin ver. 3.0: an integrated software package for population genetics data analysis. Evol Bioinform Online 2005, 1: 47-50.PubMed CentralGoogle Scholar
  79. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21(Suppl 2):263-265.View ArticlePubMedGoogle Scholar
  80. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC: PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007, 81(Suppl 3):559-575.PubMed CentralView ArticlePubMedGoogle Scholar
  81. Lowry R: McNemar’s test. http://vassarstats.net/propcorr.html
  82. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B 1995, 57(Suppl 1):289-300.Google Scholar

Copyright

© Berenguer et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement

Biological Research

ISSN: 0717-6287

Contact us